Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00628108 · ClinicalTrials.gov registry record · Phase 3
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 69
- Enrollment target
NCT00628108 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 69 participants.
The verdict
NCT00628108, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 69 participants
- Enrollment target
Study Summary
To determine the safety of levocetirizine in children ages 6-11 months with symptoms of allergic rhinitis or chronic idiopathic urticaria.
Interventions
- OTHER Placebo
- DRUG Levocetirizine 1.25 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00628108
The ClinicalTrials.gov registry entry for NCT00628108 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00628108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00628108 about?
NCT00628108 is a clinical study titled "Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months". To determine the safety of levocetirizine in children ages 6-11 months with symptoms of allergic rhinitis or chronic idiopathic urticaria.
What is the current status of trial NCT00628108?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 69 participants. The study started on 2008-03. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00628108?
The interventions under investigation include: Placebo (OTHER), Levocetirizine 1.25 mg (DRUG).
Who is sponsoring clinical trial NCT00628108?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.